Skip to main content
Download PDF

The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review

BMC Endocrine Disorders volume 22, Article number: 217 (2022) Cite this article

Abstract

Background

The data on lipid profile differences between primary aldosteronism (PA) and essential hypertension (EH) patients are inconsistent and inconclusive. Most studies reported lower levels of lipid profiles in PA than in EH. This meta-analysis aimed to explore differences in serum lipid profiles including triglyceride (TG), total cholesterol (TC), LDL and HDL levels in PA patients and EH patients.

Methods

A search of published studies was performed using PubMed, Embase and Scopus databases from their inception through August 2022. Thirty studies involving 11,175 patients were identified. Inclusion criteria included 1) observational studies which contained data on any of the lipid profiles of interest (TG, TC, LDL and HDL) which could be acquired from baseline data or the outcomes, 2) data which should be compared between adult PA and EH patients and 3) the use of appropriate methods to diagnose PA. Standardized mean difference (SMD) with a 95% confidence interval (95% CI) was calculated to assess effect size by using STATA program version 15.0. Risk of bias was assessed by Joanna Briggs Institute (JBI) Critical Appraisal Tools for cross-sectional, cohort and case-control studies.

Results

Levels of the lipid parameters TG (SMD − 0.16 mmol/L; 95%CI (− 0.25, − 0.07)), TC (SMD − 0.30 mmol/L; 95%CI (− 0.41, − 0.19)) and LDL (SMD − 0.17 mmol/L; 95%CI (− 0.27, − 0.08)) were significantly lower in PA than in EH patients. There was no statistically significant difference in HDL between PA and EH patients (SMD − 0.08 mmol/L; 96%CI (− 0.23,0.07)). High levels of heterogeneity for TG, TC, HDL and LDL were observed in all studies. Risk of bias among the studies was low to moderate.

Conclusion

Lower levels of TG, TC and LDL were observed in PA than in EH patients. Further study should be conducted to address the underlying mechanisms of lipid alteration in PA.

Peer Review reports

Introduction

Primary aldosteronism (PA), a syndrome described by autonomous excess aldosterone production, is recognized as a common form of secondary hypertension. The reported prevalence of PA ranges from 5 to 20% depending on the study, patient selection and the severity of hypertension [1]. Inappropriate aldosterone secretion in PA patients causes intravascular volume expansion, sodium retention, suppression of plasma renin level, hypertension and increased potassium secretion which can lead to hypokalemia [2]. Patients with PA were reported to be at greater risk of multiple end-organ damage, including atherosclerotic cardiovascular disease, cerebrovascular disease and renal sequelae which can cause more damage than the degree of hypertension itself, compared to essential hypertension (EH) patients [3]. Apart from the effect on intravascular volume and salt regulation, increased aldosterone levels can cause oxidative stress and proinflammatory effects on vascular walls. These effects are key mechanisms in the pathogenesis of atherosclerosis and can lead to multiple end organ damage [4]. In addition, PA has been reported to be related to metabolic syndrome and insulin resistance [5]. Also, a previous meta-analysis demonstrated a higher risk of glycemic abnormalities in PA than in EH patients. Due to the strong association of PA with atherosclerosis and metabolic syndrome, potential alteration in serum lipid profiles may be observed in some PA patients.

In normal populations without PA, multiple studies have found a positive correlation between low-density lipoprotein cholesterol (LDL), non-high-density lipoprotein cholesterol (non-HDL) and plasma aldosterone concentration, while a negative correlation with high-density lipoprotein cholesterol (HDL) has been observed [6, 7]. Deterioration of serum lipid profiles in PA patients after successful treatment by either adrenalectomy or mineralocorticoid antagonist were also observed despite an unchanged body mass index (BMI), improvement in fasting blood glucose and blood pressure [8]. Apart from PA, significant differences in lipid profiles compared to the control group were reported in some special populations, e.g., pregnancy-induced hypertension patients [9].

Dyslipidemia is a major contributor to atherosclerotic cardiovascular disease and cerebrovascular disease. According to the relationship between PA and atherosclerosis, higher probability of alteration of lipid profiles might be observed in PA than in EH patients. However, data on differences in alterations of serum lipid profiles in PA and EH patients are still inconclusive. Decreased levels of HDL in PA compared to EH has been demonstrated in some studies [10,11,12] which could be an explanatory mechanism related to the higher risk of atherosclerosis in PA than in EH. Interestingly, plasma total cholesterol (TC), triglycerides (TG), HDL and LDL have all been demonstrated to be significantly lower in PA than in EH in multiple studies [12, 13]. Also, no difference between the profiles of these lipids between PA and EH patients has been observed in several studies [14,15,16]. Because of the conflicting and inconclusive results related to serum lipid profiles in PA patients, this meta-analysis was performed to systematically elucidate differences in serum lipid profiles including TG, TC, LDL and HDL levels in PA compared to EH patients.

Materials and methods

Search strategy and selection criteria

Our meta-analysis adhered the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [17]. The prespecified protocol was registered in PROSPERO (CRD42021287330). The comprehensive search from three databases including PubMed/Medline, Scopus and Embase, was conducted from their inception to August 2022. The terms “Hyperaldosteronism OR aldosteronism OR primary aldosteronism” AND “lipid OR lipids OR cholesterol OR triglyceride OR low-density lipoprotein OR high density lipoprotein OR metabolic syndrome OR metabolic OR apolipoprotein A OR apolipoprotein B” were used as the keywords. Medical subject heading (MeSH) terms employed in the PubMed search and Emtree were employed in Embase. (For details, please see Supplementary Appendix.) To identify additional studies, a manual search was also performed of the reference lists from the included studies and from non-included reviews. Initial screening of abstracts and titles and duplicate article removal were performed using Rayyan, a web-based program (Rayyan Systems Inc., Cambridge, MA, USA) [18].

Two researchers (WM, PP) independently performed the searches, screened for titles and abstracts and reviewed full-text papers for eligibility criteria. Relevant studies from skimming titles and abstracts were retrieved for full text and were screened for eligibility criteria. Researchers (WM, PP) evaluated the methodological quality of the included studies and performed the data extraction independently. Any disagreements were debated and resolved by consensus with the third author (PA).

Eligibility criteria included the following: 1) comparative non-randomized observational studies (prospective cohort, retrospective cohort, case-control or cross-sectional study) which contained lipid profiles of at least one of the following TG, TC, LDL or HDL. The lipid profile data could be retrieved from primary outcome, baseline characteristics or baseline investigations.; 2) data should be compared between PA and EH adult patients (age ≥ 18 years).; and 3) use of appropriate methods recommended by standard guidelines for diagnosing and confirming PA [2]. Exclusion criteria were studies published in non-English language, review articles, case reports, abstracts, and animal studies. Articles including vulnerable populations such as pregnancy were also excluded. In the case of multiple studies involving the same cohort, only the study with highest number of patients was selected.

Data extraction

Two authors (WM, PP) conducted the data extraction independently. The demographic variables extracted from each study were: 1) study characteristics including the name of the first author, year of publication, country in which conducted, study design, whether the study was demographically matched between PA and EH, whether it excluded statin users, and the number of PA and EH patients; 2) patient characteristics and potential confounding factors, i.e., means and standard deviations (SD) of age, percentage of the predominant sex, predominant ethnicity, mean BMI and mean fasting plasma glucose (FPG); 3) outcome variables, i.e., mean and SD of serum lipid profiles including TG, TC, LDL and HDL in each group of PA and EH patients. Serum lipid profiles were retrieved from baseline characteristics if the endpoint of the studies were not aimed for differences of lipid levels. All the mean values were converted and presented as SI units.

Data synthesis

STATA program version 15.0 was used to perform the data analysis. Also, κ statistic to determine the level of agreement between reviewers for study selection was performed. A κ value of > 0.8 indicates excellent agreement [19]. Standardized mean difference (SMD) with a 95% confidence interval (95% CI) was analyzed to assess effect size. To estimate the statistical heterogeneity among the studies, the I2 statistic was calculated. I2 values of 25, 50 and 75% indicated low, medium and high heterogeneity, respectively [20]. We used the random-effect modeling used for the data analysis. The statistically significant level for this meta-analysis was set at p < 0.05. Publication bias was evaluated using funnel plots and Egger’s linear regression tests. The asymmetry of funnel plot demonstrated publication bias. A p-value < 0.05 indicated statistically significant publication bias for Egger’s regression.

Subgroup analysis was also performed to demonstrate the effect of age, ethnicity, BMI, FPG, demographic data matching and statin use. We performed subgroup analysis by age since some publications had reported differences in serum lipid profiles between older and younger populations [21]. Older and younger groups were categorized as mean age above and below 50 years as it has been reported that at the age of 50 years, serum lipid levels may reach their peak levels [22]. Sex was stratified based on male-predominant studies where the study population included ≥50% males. Regarding ethnicity, comparison was performed between Asians and non-Asians as a study has presented a difference in serum lipid levels between Asians and non-Asians, even in individuals with normal BMI [23]. In Asians, BMI was separated into means above and below 25 kg/m2 and in non-Asians into means above and below 30 kg/m2 [24]. BMI above and below the cut-off was used to define obese and non-obese patients, respectively. Subgroup analysis by BMI was performed as a study reported a correlation between BMI and alteration in lipid profiles [25]. FPG was categorized based on impaired fasting blood glucose criteria which was the mean blood glucose above and below 5.6 mmol/L, based on evidence that high blood glucose values are linked with significant lipid derangement of profiles [26]. Subgroup analysis was also conducted by dividing studies into those with and without data matching in order to adjust the confounders. Studies with at least one matched variable (sex, age, BMI, blood pressure or duration of hypertension) were classified to subgroups with demographic data matching. Subgroup analysis by statin use was categorized to no statin use and statin use/unknown groups. Only the outcome of TG was performed because there was only one study in the no statin use group for TC, LDL and HDL outcomes. As there were various study types included in this meta-analysis, a sensitivity analysis was also performed by removing cross-sectional studies, and only case-control and cohort studies were analyzed.

Risk of bias assessment

Assessment of the risk of bias was performed independently by two authors (WM and PP) using the Joanna Briggs Institute (JBI) Critical Appraisal Tools for cross-sectional, case-control and cohort studies [27].

Certainty of the evidence

Two authors (WM and PP) assessed the quality of the evidence independently by using Grading of Recommendation, Assessment Development and Evaluation (GRADE) methodology. The details of GRADE are available elsewhere [28]. Any conflicts were resolved by the third author (PA).

Results

The database searches yielded 6452 articles, including 3523 from PubMed, 1074 from Embase and 1855 from Scopus. From that total, 876 duplicates were removed. The titles and abstracts of 5576 articles were screened resulting in the exclusion of 5479 articles as irrelevant to our aim. The full texts of the remaining 79 articles were retrieved and reviewed resulting in the exclusion of 49 articles due to various reasons. A total of 30 studies were finally included [10,11,12,13,14,15, 29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. There was excellent inter-reviewer agreement (κ = 0.82; 95% CI, 0.71–0.92). The study selection process is shown in Fig. 1.

Fig. 1
figure 1

Flowchart of study selection process

Full size image

Study characteristics

Characteristics of the included studies are summarized in Table 1. The 30 studies included in this meta-analysis present the differences in lipid profiles in PA compared to and EH patients. Most of the studies were cross-sectional and most were conducted in non-Asian populations. All studies provided data on sex, age, ethnicity, and BMI and 23 studies provided data on FPG [11, 14, 15, 29,30,31,32,33,34,35,36,37, 39,40,41,42, 45,46,47,48,49,50,51]. Only one study excluded patients who used statins [10]. In one study, statins were withdrawn for 4 weeks prior to lipid profile evaluation [47], while five studies stated that statins were continued during the study [12, 30, 33, 40, 51]. The remaining studies did not mention this issue. One study excluded patients with severe hyperlipidemia [34]. All but one [29] of the studies provided data on TG levels, 27 included data on TC [10,11,12,13,14,15, 29, 31, 33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50, 52] and HDL levels [10,11,12,13,14,15, 29,30,31,32,33,34,35,36, 38,39,40,41, 43, 45,46,47,48,49,50,51,52] and 25 provided LDL levels [10,11,12,13,14,15, 29, 31, 33,34,35,36, 38,39,40,41, 43, 45,46,47,48,49,50,51,52].

Table 1 Baseline characteristics of the included studies
Full size table

Risk of bias in the studies

Risk of bias was evaluated using JBI tools for cross-sectional, case-control and cohort studies (Table 1). Details of the scores in each study are shown in the Supplementary Appendix. In terms of risk of bias, the majority of the studies (24 of 30) evidenced high quality with a low risk of bias [10, 12,13,14,15, 30, 32,33,34,35,36,37, 39, 41,42,43,44,45,46,47,48,49, 51, 52]. Four cross-sectional studies demonstrated moderate quality with a moderate risk of bias as important confounders had not been appropriately controlled in those studies [29, 38, 40, 50]. Two cohort studies with moderate risk of bias were not assessed regarding the outcomes issues as measured outcomes were not relevant to the primary objectives of the current study [11, 31].

Results of syntheses

A total of 11,175 patients from 30 studies were included in this meta-analysis. Forest plots of each lipid profile are shown in Fig. 2. Subgroup analysis results are showed in Table 2 and figures are shown in Supplementary Appendix. Data of publication bias are shown in Supplementary Appendix.

Fig. 2
figure 2

Forest plot of the mean difference of triglyceride (A), cholesterol (B), HDL (C) and LDL (D) levels between primary aldosteronism and essential hypertension patients

Full size image
Table 2 Subgroup analysis for assessment of lipid profiles between primary aldosteronism and essential hypertension patients
Full size table

Triglyceride

Patients with PA showed significantly lower SMD than in EH patients (SMD − 0.16 mmol/L; 95%CI (− 0.25, − 0.07)). For subgroup analysis, significantly lower TG levels were observed in PA compared to EH patients in studies of patients with normal FPG (SMD − 0.12 mmol/L; 95%CI (− 0.23, − 0.02), but not for patients with mean FPG in the impaired range. Significantly lower TG levels were observed in PA compared to EH patients in the subgroups of age, ethnicity, BMI, demographic data matching and statin use. In TG studies, moderate heterogeneity (I2 = 69.9, p < 0.001) was observed. Ethnicity was found to be the cause of heterogeneity. Studies performed in groups where Asians predominated were more homogeneous than the those done in groups that were predominately non-Asians. Egger’s regression test did not reveal any publication bias for TG with p = 0.191.

Total cholesterol

PA patients demonstrated significantly lower cholesterol levels than EH patients (SMD − 0.30 mmol/L; 95%CI (− 0.41, − 0.19)). For subgroup analysis, as in the general findings, PA patients generally had significantly lower TC than EH patients for the subgroups of age, ethnicity, BMI, FPG, and demographic data matching. There was high heterogeneity among the studies in TC and HDL levels (I2 = 75.9%, p < 0.001)). Ethnicity distribution, mean BMI and FPG and whether the demographic data had been matched were sources of heterogeneity The studies conducted mainly in Asians and those with unmatched demographic data showed more homogeneous patterns than other subgroups. Also, studies of predominantly obese patients and those with impaired fasting glucose were more homogeneous than other subgroups. Egger’s regression test did not reveal any publication bias for TC with p = 0.050.

High-density lipoprotein cholesterol

There was no statistically significant difference in HDL levels between the PA and EH groups (SMD − 0.08 mmol/L; 96%CI (− 0.23, 0.07)). Regarding subgroup analysis, HDL levels were found to be significantly lower in studies with non-Asians, studies with a mean patient age ≥ 50 years, and studies with mean FPG in the impaired-fasting range. Non-significant trends in the same direction were observed in subgroups with predominantly Asians, and patients with a mean age < 50 years and patients with a mean FPG in the normal range. The were no differences in HDL levels between PA and EH patients on BMI and demographic data matching subgroups. There was high heterogeneity among the studies in HDL levels (I2 = 87%, p < 0.001)). Mean BMI was the only source of heterogeneity. Studies performed predominantly in patients with mean BMI in the non-obese range were more homogeneous than those with mostly obese patients. Egger’s regression test did not reveal any publication bias for HDL with p = 0.821.

Low-density lipoprotein cholesterol

Patients with PA showed significantly lower levels than those with EH (SMD − 0.17 mmol/L; 95%CI (− 0.27, − 0.08)). For subgroup analysis, significantly lower levels in PA than in EH were reported in studies with predominantly non-obese patients, mean glucose in the normal range and studies with demographic data matching. Non-significant trends in the same direction were found in subgroups of studies with predominantly obese patients, patients with mean glucose in the impaired range and in non-matching demographic data. PA patients in both age groups and of both ethnicity categories showed significantly lower levels of LDL than EH patients. There was moderate heterogeneity among the studies in LDL levels (I2 = 65.7%, p < 0.001)). Ethnicity and mean FPG were the main sources of heterogeneity. Studies with Asian-predominant patients and normal mean FPG were more homogeneous than other subgroups. Egger’s regression test did not reveal any publication bias for LDL with p = 0.311.

Sensitivity analysis

By removing cross-sectional studies from the analysis, results for TC, HDL and LDL remained the same as in the previous analysis. Significantly lower levels of TC and LDL in PA than in EH patients were observed (SMD − 0.35 mmol/L; 95%CI (− 0.56, − 0.13), SMD − 0.30 mmol/L; 95%CI (− 0.40, − 0.19), respectively) and no significant differences of HDL were observed between PA and EH patients (SMD 0.08 mmol/L; 95%CI (− 0.50, 0.65). The results of TG showed no statistically significant difference between the PA and EH groups, which was different from the primary analysis (SMD − 0.28 mmol/L; 95%CI (− 0.78, 0.22)). Regarding heterogeneity among studies, only results for LDL showed an improvement in the heterogeneity. Forest plots of the sensitivity analysis are shown in Fig. 3.

Fig. 3
figure 3

Forest plot of the sensitivity analysis presented by mean difference of triglyceride (A), cholesterol (B), HDL (C) and LDL (D) levels between primary aldosteronism and essential hypertension patients

Full size image

Certainty of the evidence

The initial assessments for certainty of evidence for TG, TC and LDL SMD values were low due to the observational studies (2+). Considering the moderate to low risk of bias (no rating change), the large heterogeneity in all studies (downgrade one level), indirectness (no rating change), low imprecision and the absence of publication bias (no rating change), the overall level of certainty was very low (1+). For HDL SMD levels, the initial assessment showed low certainty of evidence (2+). There was a high degree of imprecision according to the wide CI with threshold crossing (downgrade one level) and the large heterogeneity in the studies (downgrade one level). Other aspects required no rating change. Therefore, the overall level of certainty was very low for HDL (1+).

Discussion

This meta-analysis is the first to investigate differences in serum lipid profiles, including TG, TC, HDL and LDL, between PA and EH patients. The study found significant differences in the direction of lower TG, TC and LDL in PA patients than in EH patients. HDL levels were not significantly different between PA and EH patients, but did show a trend toward lower HDL in PA than in EH patients.

It has been demonstrated that dyslipidemia can contribute to an increased risk of atherosclerotic events and cardiovascular complications [53]. In patients with PA, increased risk of atherosclerotic cardio- and cerebrovascular disease has also been observed [54]. The evidence regarding whether dyslipidemia is the cause of these atherosclerotic events in PA is still inconclusive. Evidence of a relationship between plasma aldosterone and alteration of lipid levels in the general population without PA has been reported. However, the association was different to our meta-analysis findings. In patients with metabolic syndrome and without PA, increased plasma aldosterone has been shown to be related to increased TG, LDL and decreased HDL levels [6, 55, 56]. Furthermore, research conducted as part of the Framingham offspring study in participants without metabolic syndrome demonstrated that increased plasma aldosterone levels are linked with an increased TC/HDL ratio but are not associated with HDL levels alone [57]. The explanation underpinning this relationship has been widely discussed but is still inadequately understood. One of the proposed theories is that secretion factors from adipose tissue can stimulate aldosterone secretion, which, in turn, acts on the mineralocorticoid receptor that can mediate adipogenesis [58]. Another hypothesis is that high aldosterone levels can provoke acute renal failure which, as a consequence, can then alter LDL and HDL production [59].

Unlike the situation in the general population, our meta-analysis of lipid levels, including TG, TC and LDL, in PA patients showed significantly lower levels than in EH patients. Lower plasma TG in PA than in EH patients could be the result of glomerular hyperfiltration caused by hypertension and to the increased plasma volume which is commonly observed in PA patients [60]. Increased levels of TG can be observed in chronic renal failure patients, a result of low activity of lipoprotein lipase (LPL) which facilitates clearance of TG and reduction of TG levels [61]. Thus, an increase in the estimated glomerular filtration rate (eGFR) in PA patients can contribute to increases in LPL activity which results in increased TG clearance and, finally, decreased TG levels. An interesting study supporting this hypothesis reported that successfully treated PA patients showed worsening TG levels despite improvement in blood pressure and glucose levels which could be explained by the decline in glomerular filtration after adrenalectomy [8]. Currently, the mechanism responsible for lower TC and LDL in PA patients than in EH patients is still uncertain. Circulating lipoproteins are the source of precursors of adrenal steroidogenesis, including aldosterone production. However, it cannot be directly inferred that increased production of aldosterone in PA can cause the depletion of TC and LDL and lead to levels reduction [62]. Another possible explanation could relate to liver X receptors (LXR) which are involved in cholesterol metabolism. It is known that LXR stimulation can increase renin and aldosterone accumulation, but whether the existence of a backward causation effect of aldosterone can stimulate LXR is still unclear [63]. Moreover, there were other factors which could affect lipid profiles, including genetic mutations, diet, physical activity, obesity, smoking, diabetes mellitus, hypothyroidism, liver diseases, renal function, and some medications. Regarding medications, thiazide type diuretics, which is an anti-hypertensive medication commonly used in EH, could lead to increased TG, TC, and LDL, while mineralocorticoid receptor blockers, the drug of choice for PA, have no effect on lipid profiles. This could be one of the explanations for the different lipid changes between PA and EH [64]. Nevertheless, these factors, which can interfere with lipid levels, were not reported in the included studies. Future studies to address the link between PA and these factors are warranted.

Significantly lower levels of TG, TC and LDL in PA than in EH patients were an unexpected finding taking into consideration the relatively high incidence of atherosclerotic events, metabolic syndrome and insulin resistance in PA patients [37, 65]. These findings may be used as a guide for the clinicians to differentiate between PA and EH, in which, those with low levels of TG, TC and LDL, PA should be suspected. Nevertheless, future research regarding this issue should be warranted.

As mentioned above, increased aldosterone levels can cause oxidative stress and pro-inflammatory effects on vascular walls; this is in line with the recent observation that elevated secretion of aldosterone increases oxidized small dense LDL, as indirectly measured by the TG/HDL-C ratio [66]. It is therefore likely that patients with primary aldosteronism may have alterations in both the quantity and the quality of LDL, with reduced LDL concentrations but with increased levels of atherogenic small dense LDL [67]; these particles are strongly associated with atherosclerosis formation and progression [68]. Moreover, it is known that elevated aldosterone levels is associated with elevated levels of pro-inflammatory adipokines such as resistin [36], which are also strongly associated with atherogenic small dense LDL [69] and therefore potentially enhancing the atherosclerotic process.

However, due to the moderate to high heterogeneity among the studies, the results of this review should be interpreted cautiously. Concerning the heterogeneity issue, confounders which could potentially interfere with the levels of lipid profiles were addressed by subgroup analyses. In terms of ethnicity, non-Asian predominant studies reported lower levels of TG, TC and LDL in PA than in EH patients. Asian populations demonstrated an increased trend of age-standardized non-HDL cholesterol and cholesterol levels to a greater extent than did Caucasians [70]. Available data showed that the maximum doses of statins used in Western countries were higher than in Asian countries [71]. This may be the result of differences in lipid profiles between the ethnic groups. However, the direct relationship between ethnicity and levels of aldosterone and lipids has not yet been clearly elucidated. Data on dosages and percentages of statin use was not provided in the studies included in this meta-analysis.

Levels of TC and HDL were observed to be lower in PA than in EH, particularly in studies with non-obese patients predominant. We surmised that non-obese patients with PA may have a higher risk of diabetes than EH patients due to increased insulin resistance from high aldosterone [72]. This is consistent with previous suggestions on a patho-physiological link between diabetic lipoproteins and adrenal aldosterone synthesis [73]. Diabetic patients seem to be more likely to have been prescribed statins, resulting in lower cholesterol levels. However, data on diabetes prevalence and statin use was not provided in the included studies. TC and LDL levels were observed to be lower in PA than in EH patients only in studies with mean FPG in the impaired glucose level range. As noted above, patients diagnosed with impaired fasting glucose were more likely to be prescribed statins than those with normal glucose. Levels of TC were significantly lower in PA than in EH patients only in those studies that have been matched for demographic data. This could indicate that after removing demographic confounders using case-control matching, the remaining difference in lipid levels between PA and EH patients was real.

A sensitivity analysis by removing cross-sectional studies was performed, and only cohort or case-control studies were analyzed. The reason behind this sensitivity analysis is that a cross-sectional study can determine the prevalence or associations rather than causality, whereas a cohort or case-control study can establish the timing and directionality of events. The results remained almost the same as in the previous analysis, except for that of TG. However, since the main objectives of most of the cohort and case-control studies were not aimed at finding the differences in lipid profiles between PA and EH patients, the type of study design may not play a major role in the outcomes.

One of the strengths of this first meta-analysis to address the difference in lipid parameters between PA and EH patients is that only studies which had clear criteria to diagnose PA were selected. Another strength is that subgroup analysis was performed to identify the effects of potential confounders and to identify causes of heterogeneity.

There are, however, several limitations that needed to be acknowledged. The main limitation is the high level of heterogeneity among the included studies, even though subgroup analyses were conducted to investigate the sources and impacts of the heterogeneity. Second, the primary objectives of most of the studies did not aim to find the differences in lipid profiles between PA and EH patients. Additionally, most of the lipid data used in the meta-analyses were obtained from baseline characteristics. That may have affected outcomes as some confounders, e.g., sex, age, BMI and blood pressure, were not matched prior to the analysis. However, in the analyses of subgroups established by demographic data matching, TG, HDL and LDL levels were still significantly lower in PA than in EH patients. Third, only two of the studies excluded patients who had used statins prior to the analyses which could have affected lipid measurements. Nevertheless, subgroup analysis by statin use showed similar TG result between two subgroups of no statin group and statin use/unknown status of use group. Additionally, lifestyle, activity level, diet and genetics may possibly affect lipid profiles, but most of the studies did not provide information regarding these factors. Also, the measurement of lipid profiles, especially LDL levels, can be performed by either a direct measurement method or by using various equations. However, the method employed to measure LDL was not reported in the included studies. This can lead to different results for LDL among the studies [74].

Conclusion

Compared to EH patients, PA patients had unexpectedly and significantly lower levels of lipid parameters including TG, TC and LDL. This indicates that increased atherosclerotic cardiovascular events in PA patients are not a result of differences in lipid levels. Further research is required to address the mechanisms involved in lipid metabolism in PA.

Availability of data and materials

The datasets used and/or analysed during the current study are available at https://www.dropbox.com/s/f1bz1g0tsx0ezjg/raw%20data%20new1.xlsx?dl=0

Abbreviations

BMI:

Body mass index

CI:

Confidence interval

EH:

Essential hypertension

FPG:

Fasting plasma glucose

HDL:

High density lipoprotein

LDL:

Low density lipoprotein

PA:

primary aldosteronism

SMD:

Standardized mean difference

TC:

Total cholesterol

TG:

Triglyceride

References

  1. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011;2011:162804.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.

    Article  CAS  PubMed  Google Scholar 

  3. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary Aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23(12):1253–60.

    Article  CAS  PubMed  Google Scholar 

  4. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51(2):161–7.

    Article  CAS  PubMed  Google Scholar 

  5. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48(2):239–45.

    Article  CAS  PubMed  Google Scholar 

  6. Hannich M, Wallaschofski H, Nauck M, Reincke M, Adolf C, Völzke H, et al. Physiological aldosterone concentrations are associated with alterations of lipid metabolism: observations from the general population. Int J Endocrinol. 2018;2018:4128174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25(1):30–6.

    Article  CAS  PubMed  Google Scholar 

  8. Adolf C, Asbach E, Dietz AS, Lang K, Hahner S, Quinkler M, et al. Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine. 2016;54(1):198–205.

    Article  CAS  PubMed  Google Scholar 

  9. Shihab AS, Hamdi MA, Jumaa AM, Marbut MM, Jwad SK. Dyslipidemia and other parameters in women with pregnancy induced hypertension. J Popul Ther Clin Pharmacol. 2022;29(1):e116–21.

    PubMed  Google Scholar 

  10. Moon SJ, Jang HN, Kim JH, Moon MK. Lipid profiles in primary Aldosteronism compared with essential hypertension: propensity-score matching study. Endocrinol Metab (Seoul). 2021;36(4):885–94.

    Article  CAS  Google Scholar 

  11. Turchi F, Ronconi V, di Tizio V, Ceccoli L, Boscaro M, Giacchetti G. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. Nutr Metab Cardiovasc Dis. 2014;24(5):476–82.

    Article  CAS  PubMed  Google Scholar 

  12. Berends AMA, Buitenwerf E, Gruppen EG, Sluiter WJ, Bakker SJL, Connelly MA, et al. Primary aldosteronism is associated with decreased low-density and high-density lipoprotein particle concentrations and increased GlycA, a pro-inflammatory glycoprotein biomarker. Clin Endocrinol. 2019;90(1):79–87.

    Article  CAS  Google Scholar 

  13. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60(3):618–24.

    Article  CAS  PubMed  Google Scholar 

  14. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2009;53(4):605–10.

    Article  CAS  PubMed  Google Scholar 

  15. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary Aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–20.

    Article  PubMed  Google Scholar 

  16. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, et al. Adiponectin and insulin sensitivity in primary Aldosteronism. Am J Hypertens. 2007;20(8):855–61.

    Article  CAS  PubMed  Google Scholar 

  17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.

    Article  PubMed  PubMed Central  Google Scholar 

  19. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, for GG. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). Can Med Assoc J. 2004;171(11):1369–73.

    Article  Google Scholar 

  20. Rangaswamaiah S, Gangathimmaiah V, Nordenstrom A, Falhammar H. Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:493.

    Article  Google Scholar 

  21. Johnson AA, Stolzing A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease. Aging Cell. 2019;18(6):e13048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. Jama. 2005;294(14):1773–81.

    Article  CAS  PubMed  Google Scholar 

  23. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53(3):244–53.

    Article  CAS  PubMed  Google Scholar 

  24. Weisell RC. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr. 2002;11(s8):S681–4.

    Article  Google Scholar 

  25. Hussain A, Ali I, Kaleem WA, Yasmeen F. Correlation between body mass index and lipid profile in patients with type 2 diabetes attending a tertiary care hospital in Peshawar. Pak J Med Sci. 2019;35(3):591–7.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kaur G, Sudhera N, Singh K, Singh G, Bassi DK. Effect of fasting blood glucose (FBG) on lipid metabolism and gender differences in the pattern of dyslipidemia in adults with type 2 diabetes in northern India. Stud Ethno-Med. 2017;11(3):209–15.

    Article  Google Scholar 

  27. Moola SMZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, et al. Mu P-F chapter 7: systematic reviews of etiology and risk. In: Aromataris EMZ, editor. JBI manual for evidence synthesis JBI; 2020.

    Google Scholar 

  28. Schünemann HBJ, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations updated October (2013) the GRADE working group (2013); 2013.

    Google Scholar 

  29. Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimský J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens. 2006;19(9):909–14.

    Article  PubMed  Google Scholar 

  30. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9.

    Article  CAS  PubMed  Google Scholar 

  31. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457–63.

    Article  CAS  PubMed  Google Scholar 

  32. Ronconi V, Turchi F, Rilli S, Di Mattia D, Agostinelli L, Boscaro M, et al. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis. 2010;20(2):93–100.

    Article  CAS  PubMed  Google Scholar 

  33. Somlóová Z, Widimský J Jr, Rosa J, Wichterle D, Strauch B, Petrák O, et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010;24(10):625–30.

    Article  PubMed  CAS  Google Scholar 

  34. Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens. 2010;23(1):2–5.

    Article  CAS  PubMed  Google Scholar 

  35. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 2010;28(10):2120–6.

    Article  CAS  PubMed  Google Scholar 

  36. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95(5):2391–8.

    Article  CAS  PubMed  Google Scholar 

  37. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–6.

    Article  CAS  PubMed  Google Scholar 

  38. Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska H, Bieleń P, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynol Pol. 2013;64(5):363–7.

    Article  CAS  PubMed  Google Scholar 

  39. Liu G, Yin GS, Tang JY, Ma DJ, Ru J, Huang XH. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J Hum Hypertens. 2014;28(12):711–5.

    Article  CAS  PubMed  Google Scholar 

  40. Choudhary MK, Värri E, Matikainen N, Koskela J, Tikkakoski AJ, Kähönen M, et al. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension. J Intern Med. 2021;289(1):29–41.

    Article  CAS  PubMed  Google Scholar 

  41. Yang Y, Zhu LM, Xu JZ, Tang XF, Gao PJ. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. Hypertens Res. 2017;40(3):243–50.

    Article  PubMed  Google Scholar 

  42. Watanabe D, Yatabe M, Ichihara A. Evaluation of insulin sensitivity and secretion in primary aldosteronism. Clin Exp Hypertens. 2016;38(7):613–7.

    Article  CAS  PubMed  Google Scholar 

  43. Li H, Liu J, Liu J, Liu L, Huang M, Wei G, et al. The association between a 24-hour blood pressure pattern and circadian change in plasma aldosterone concentration for patients with aldosterone-producing adenoma. Int J Endocrinol. 2019;2019:4828402.

    PubMed  PubMed Central  Google Scholar 

  44. Er LK, Lin MC, Tsai YC, Hsiao JK, Yang CY, Chang CC, et al. Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma. BMJ Open Diabetes Res Care. 2020;8(1)1-8.

  45. Vujačić N, Paunović I, Diklić A, Živaljević V, Slijepčević N, Kalezić N, et al. Biochemical and clinical characteristics of patients with primary aldosteronism: single Centre experience. J Med Biochem. 2020;39(2):240–8.

    PubMed  PubMed Central  Google Scholar 

  46. Manosroi W, Atthakomol P. High body fat percentage is associated with primary aldosteronism: a cross-sectional study. BMC Endocr Disord. 2020;20(1):175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhang SL, Gao JW, Guo Y, Feng QL, Tang JY, Yan L, et al. Associations between metabolic profiles and target-organ damage in Chinese individuals with primary Aldosteronism. Front Endocrinol (Lausanne). 2020;11:547356.

    Article  Google Scholar 

  48. Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary Aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol Metab. 2020;105(4)1079-85.

  49. Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38(9):1841–8.

    Article  CAS  PubMed  Google Scholar 

  50. Sang M, Fu Y, Wei C, Yang J, Qiu X, Ma J, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension. J Renin-Angiotensin-Aldosterone Syst. 2021;22(1):1470320321999491.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Fernández-Argüeso M, Pascual-Corrales E, Bengoa Rojano N, García Cano A, Jiménez Mendiguchía L, Araujo-Castro M. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine. 2021;73(2):439–46.

    Article  PubMed  CAS  Google Scholar 

  52. Huang X, Yu S, Xiao H, Pei L, Chen Y, Chen W, et al. Comparison of clinical features between primary Aldosteronism and essential hypertension in Chinese patients: a case-control study. Int J Endocrinol. 2021;2021:6685469.

    PubMed  PubMed Central  Google Scholar 

  53. Yaghi S, Elkind MSV. Lipids and cerebrovascular disease: research and practice. Stroke. 2015;46(11):3322–8.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(26):e15985.

    Article  Google Scholar 

  55. Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson heart study. Diabetes Care. 2013;36(10):3084–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hannemann A, Meisinger C, Bidlingmaier M, Döring A, Thorand B, Heier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164(5):751–8.

    Article  CAS  PubMed  Google Scholar 

  57. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham heart study. Am J Hypertens. 2005;18(5 Pt 1):657–65.

    Article  CAS  PubMed  Google Scholar 

  58. Caprio M, Fève B, Claës A, Viengchareun S, Lombès M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21(9):2185–94.

    Article  CAS  PubMed  Google Scholar 

  59. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16(5):1320–5.

    Article  PubMed  Google Scholar 

  61. Ćwiklińska A, Cackowska M, Wieczorek E, Król E, Kowalski R, Kuchta A, et al. Progression of chronic kidney disease affects HDL impact on lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency. Kidney Blood Press Res. 2018;43(3):970–8.

    Article  PubMed  CAS  Google Scholar 

  62. Buitenwerf E, Dullaart RPF, Muller Kobold AC, Links TP, Sluiter WJ, Connelly MA, et al. Cholesterol delivery to the adrenal glands estimated by adrenal venous sampling: an in vivo model to determine the contribution of circulating lipoproteins to steroidogenesis in humans. J Clin Lipidol. 2017;11(3):733–8.

    Article  PubMed  Google Scholar 

  63. Maqdasy S, Trousson A, Tauveron I, Volle DH, Baron S, Lobaccaro JM. Once and for all, LXRα and LXRβ are gatekeepers of the endocrine system. Mol Asp Med. 2016;49:31–46.

    Article  CAS  Google Scholar 

  64. Mantel-Teeuwisse AK, Kloosterman JM. Maitland-van der zee AH, Klungel OH, Porsius AJ, de Boer a: drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001;24(6):443–56.

    Article  CAS  PubMed  Google Scholar 

  65. Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44(3):208–14.

    Article  CAS  PubMed  Google Scholar 

  66. Zhang Q, Pan Y, Ma X, Yang H, Chang J, Hong L, et al. Elevated secretion of aldosterone increases TG/HDL-C ratio and potentiates the ox-LDL-induced dysfunction of HUVEC. Cell J. 2021;23(1):61–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract. 2007;61(11):1949–56.

    Article  CAS  PubMed  Google Scholar 

  68. Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol basis Dis. 2018;1864(9 Pt B):2814–21.

    Article  CAS  PubMed  Google Scholar 

  69. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20(31):4961–9.

    Article  CAS  PubMed  Google Scholar 

  70. NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73–7.

  71. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24(1):19–25.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC, et al. Primary Aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension. 2020;75(5):1251–9.

    Article  CAS  PubMed  Google Scholar 

  73. Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis--a possible pathophysiological link? Horm Metab Res. 2012;44(3):239–44.

    Article  CAS  PubMed  Google Scholar 

  74. Rerksuppaphol L, Rerksuppaphol S. Comparison of equations for the calculation of low-density lipoprotein cholesterol in Thai population. J Nat Sci Biol Med. 2021;12(2):224–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Dr. Lamar G. Robert and Dr. Chongchit A. Robert for reviewing the manuscript.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Intrawarorot Road Soi 2, Si Phum, Amphoe Mueang Chiang Mai, Chiang Mai, 50200, Thailand

    Worapaka Manosroi, Pitchaporn Phudphong & Mattabhorn Phimphilai

  2. Orthopaedics Department, Faculty of Medicine, Chiang Mai University, Muang Chiang Mai, Chiang Mai, Thailand

    Pichitchai Atthakomol

  3. Clinical Epidemiology and Clinical Statistic Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Pichitchai Atthakomol

Authors
  1. Worapaka Manosroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pitchaporn Phudphong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pichitchai Atthakomol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mattabhorn Phimphilai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

W.M. designed the study, collected, analyzed, and interpreted the data, and was the major contributor in writing the manuscript. P.P. collected and performed data analyzed. P.A. designed the study and performed the data analyses. M. P reviewed and edited the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Worapaka Manosroi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Keywords of articles searching. Table S2.1. Risk of bias assessed by Joanna Briggs Institute (JBI) Critical Appraisal Tools for cross-sectional study. Table S2.2. Risk of bias assessed by Joanna Briggs Institute (JBI) Critical Appraisal Tools for case-control study. Table S2.3. Risk of bias assessed by Joanna Briggs Institute (JBI) Critical Appraisal Tools for cohort study. Figure S1. Subgroup analysis by age group. Figure S2. Subgroup analysis by age group. Figure S3. Subgroup analysis by BMI. Figure S4. Subgroup analysis by blood glucose. Figure S5. Subgroup analysis by demographic data matching. Figure S6. Subgroup analysis by statin use. Figure S7. Funnel plots.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manosroi, W., Phudphong, P., Atthakomol, P. et al. The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review. BMC Endocr Disord 22, 217 (2022). https://doi.org/10.1186/s12902-022-01135-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-022-01135-y

Keywords

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us